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Breast conserving surgery has been accepted as the optimal local therapy for women with early breast cancer, emphasizing the
necessity to balance oncologic goals with patient satisfaction and cosmetic outcomes. In the move to enhance a surgeon’s ability
to achieve histologically clear margins intraoperatively at the initial surgery, the MarginProbe (Dune Medical Devices, Caesarea,
I s r a e l )h a se m e r g e da sa ne ﬀective tool to accomplish that task. Based on previously reported success using the device, we assessed
cosmesis and tissue resection volumes among participants in a randomized-controlled trial comparing the standard of care
lumpectomy performed with and without the MarginProbe. The use of the MarginProbe device resulted in a 57% reduction
in reexcision rates compared to the control group with a small increase in tissue volume removed at the primary lumpectomy.
When total tissue volumes removed were analyzed, the device and control groups were still very similar after normalization to bra
cup size. We concluded that the MarginProbe is an eﬀective device to assist surgeons in determining margin status intraoperatively
while allowing for better patient cosmetic outcomes due to the smaller volumes of tissue resected and the reduction in patient
referrals for second surgeries due to positive margins.
1.Introduction
Since the acceptance of breast conserving surgery with radio-
therapy as a standard of care for early stage breast cancer
[1], the National Comprehensive Cancer Network guidelines
for breast cancer treatment recommend the assessment of
surgical margins to aide in local control of disease. Any
marginsdeemedpositiveshouldbeconsideredforadditional
surgery according to these guidelines since clear surgical
margins have been shown to minimize the risk of local
recurrence [2].
The optimal time to identify positive margins is at the
time of the initial operation since it aﬀords the opportunity
to reexcise positive or questionable margins without subject-
ing the patient to a second operation. The eﬀort to achieve
clear surgical margins intraoperatively is aided by surgeon’s
judgment, specimen palpation, gross sectioning, imaging
[3], wire localization, frozen section, and touch prep analysis
[4], among other techniques. In spite of these eﬀorts, up to
40% of women in the USA continue to undergo multiple
operations due to initial failure to achieve clear margins.
To further reduce the need for reexcisions, the Margin-
Probe (Dune Medical Devices, Caesarea, Israel) was devel-
oped to provide real-time, intraoperative assessment of the
presence of disease at the surgical margins. The Margin-
Probe is a handheld device that utilizes radiofrequency
spectroscopy to detect electromagnetic changes in malignant
tissue within 1mm of the margin surface. A 21-center
randomized, controlled trial (Pivotal Trial) was conducted to
determine if the adjunctive use of the MarginProbe would2 International Journal of Surgical Oncology
enhance standard of care practices employed by surgeons
to reduce the need for reexcision procedures. While the
complete results of this study are still awaiting publication,
the use of the MarginProbe has been validated in other
s t u d i e sa sa ne ﬀective way to assess margins intraoperatively
because of its high sensitivity in identifying malignant tissue
and high speciﬁcity in distinguishing between normal and
malignant tissues [5, 6].
A central question in the Pivotal Trial was whether or
not the use of the MarginProbe device would result in the
resection of excessively wide margins, thereby producing an
adverse eﬀect on cosmesis. Herein, we present the analysis
of the cosmetic impact of intraoperative margin assessment
using the MarginProbe on the participants in the Pivotal
Trial.
2.MaterialsandMethods
Six hundred and sixty-four (664) women with nonpalpable
invasive cancer and/or DCIS undergoing lumpectomy were
enrolled in the Pivotal Trial at 21 institutions. Following
“standardofcare(SOC)”lumpectomy,596womenwereran-
domized (1:1) intraoperatively to MarginProbe device use
or control (i.e., SOC only with no device use). The deﬁnition
of SOC varied by institution, but typically involved wire
localization, specimen palpation, specimen radiography, and
reexcision of questionable margins. Frozen section, touch
prep analysis, and gross sectioning were not permitted to
avoid confounding subsequent margin analysis. In women
randomized to the device arm, the MarginProbe was used
to assess each margin of the resected surgical specimen.
The 7mm sensor footplate at the probe tip was applied
to a minimum of 5 sites and a maximum of 8 sites on
each margin surface, depending on the area of each margin
surface. A vacuum mechanism ensured full contact of the
7mm sensor with the margin surface (Figure 1). An auditory
and visual binary signal (positive/negative) was produced
when the MarginProbe detected the presence or absence of
malignanttissueswithin1mmofthemarginsurfaceatanyof
the 5–8 examined sites (Figure 2). By protocol requirements,
any margin producing a positive reading required the
reexcision of the entire aﬀected margin. The thickness of
each margin was left to the discretion of the operating
surgeon. Skin margins and muscle margins did not require
reexcision. Women randomized to the SOC arm underwent
no additional margin resection following randomization.
Surgeons were discouraged from taking additional shave
margins as a safeguard against randomization to the SOC
arm. Excision of shave margins following randomization
to the SOC arm was considered a protocol violation and
resulted in censuring of the data.
All primary and reexcision specimens in both arms were
submitted for standard histopathological examination by
pathologists who were blinded to the study arm. Device
readings were compared per specimen for histological
assessment of the initially excised lumpectomy specimens.
True positive device readings occurred when invasive
breast cancer or DCIS was detected histologically less than
1mm from original specimen margin. True negative device
readings occurred when histopathology of the primary
specimen revealed no malignant cells within 1mm of the
corresponding margin surface.
The ability to correctly and intraoperatively identify all
of the involved margins on the main specimen and reexcise
them was deﬁned as a correct Complete Surgical Resection
(CSR). Correctness or incorrectness of CSR was deﬁned
based on permanent histology data. CSR was deﬁned as
correct only when all main specimen margins detected as
positive by histology were reexcised intraoperatively.
3. Results
The breakdown of tissue volume removed is shown in
Table 1. When analyzing the impact of the MarginProbe
on reexcision rates, the use of the device resulted in a
57% reduction in reexcision compared to the control group
(device: 42/298 (14.1%), Control: 98/298 (29.9%), 57%
reduction, P<0.0001). As a result of true positive and
false positive device readings, there was a small increase in
tissue volume removed at primary lumpectomy (15.6cc and
less than 2 shavings per patient). Among patients requiring
reexcision of positive margins at a second operation, less
tissue was ultimately removed in the device arm (device:
28.4cc, control: 49.5cc, a 43.4% reduction). When analyzing
the total tissue volumes removed (all operations combined),
resectedtissuevolumewasonlyslightlygreater(8.5cc)inthe
device arm (2.6% greater when normalized to bra cup size).
4. Discussion
It is well established that cosmesis after breast conserving
surgery is aﬀected by multiple variables. Among the most
important are the need for reexcision as well as surgery the
amount of tissue removed at the primary and secondary
surgeries [7–9]. Accurate intraoperative assessment of surgi-
cal margins allows the tumor to be removed in one surgical
procedure, thereby sparing patients the burden of a second
breast operation. However, standard of care approaches for
intraoperative margin assessment (e.g., palpation, gross-
sectioning of the specimen, specimen imaging, wire localiza-
tion, and frozen section or touch prep analysis) continues
to be commonly associated with margin reexcision rates
of 20–40%. Reexcision has been associated with the risk
of postoperative infection, delays in the onset of adjuvant
therapy, lower patient satisfaction, lower rates of cosmetic
acceptability, increased medical costs, and stress for patients
who sometimes needlessly elect mastectomy rather than risk
another positive margin [7–11]. Based on the results of the
Pivotal Trial, breast reexcisions can be signiﬁcantly reduced
with the use of the MarginProbe device which should, in
turn, signiﬁcantly improve the safety and feasibility of breast
conserving surgery.
In spite of its beneﬁts in reducing breast reexcisions,
concerns have been expressed that the adjunctive use of the
MarginProbe might compromise breast cosmesis due to the
excessive resection of breast tissue, particularly when falseInternational Journal of Surgical Oncology 3
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Figure 1: Photograph (a) of MarginProbe device showing vacuum mechanism that ensures full contact of the 7mm sensor with the margin
surface. Schematic (b) showing 7mm diameter sensor and radiofrequency ﬁeld that penetrates margin surface to detect cancer-associated
electromagnetic changes.
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Figure 2: Visual binary signal display showing either positive
(Pos.) or negative (Neg.) margin at multiple sites measured on
each specimen margin surface [deep (D), anterior (A), inferior (I),
superior (S), lateral (L), and medial (M)].
positive readings are encountered. However, comparison of
the device and control arms in the Pivotal Trial showed
minimal impact on breast cosmesis when analyzed by the
volume of resected breast tissue. In fact, only 2.6% greater
volume was resected in the device arm when normalized
to breast size. This corresponded to 2 additional margin
shavings per patient, which is less than the 4–6 margins
that may be indiscriminately reexcised by some surgeons
whoroutinelyharvestmarginshavings.Furthermore,among
patients who ultimately required reexcision at a second
operation,therewasessentiallynodiﬀerenceinthetwostudy
arms (−1.6% diﬀerence, normalized) in the total volume of
resected breast tissue. Collectively, these ﬁndings resolved
concerns that the use of the MarginProbe may adversely
aﬀect cosmesis.
5. Conclusion
The primary goal of breast conserving surgery is resection
of breast malignancy with clear margins and acceptable
cosmesis. While this goal is not always achievable at the
initial operation, every reasonable eﬀort should be made
avoid multiple surgeries, undesirable cosmetic outcomes,
Table 1: Total tissue volume removed.
Average per patient Control Device Diﬀerence
Initial surgery
Main specimen 61.3cc 59.7cc −1.6cc
True positive shavings 2.7cc 6.7cc 4.0cc
False positive shavings 7.7cc 21.1cc 13.4cc
Total volume 71.9cc 87.5cc 15.6cc
Reexcision surgeries
Tissue volume 49.5cc 28.4cc −21.1cc
Normalized tissue volume
(normalized to breast volume)
5.6% 4.0% −1.6%
All surgeries
Total tissue volume 84.8cc 93.3cc 8.5cc
Normalized total tissue volume
(normalized to breast volume)
12.5% 15.1% 2.6%
increased treatment burden, and increased medical costs
associated with these factors. The MarginProbe represents
a practical advancement in the ﬁeld of surgical specimen
margin evaluation. When combined with the standard of
care techniques, the MarginProbe may signiﬁcantly lower
the rates of reexcision for breast cancer patients, achieve
comparable tissue volume removal at the ﬁrst surgery,
and reduce the amount of tissue removed among patient
requiring a second operation. The end result is signiﬁcant
quality improvement in the management of conservatively
treated breast cancer patients.
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